I-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
I-Mab (NASDAQ:IMAB) Full Year 2023 Results
Key Financial Results
Net loss: CN¥1.47b (loss narrowed by 39% from FY 2022).
CN¥16.53 loss per share (improved from CN¥29.23 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
I-Mab Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 43%. Earnings per share (EPS) missed analyst estimates by 32%.
In the last 12 months, the only revenue segment was Biotechnology contributing CN¥27.6m. The largest operating expense was Research & Development (R&D) costs, amounting to CN¥810.6m (54% of total expenses). Explore how IMAB's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 2.8% from a week ago.
Risk Analysis
Be aware that I-Mab is showing 3 warning signs in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
